SCHEMBL497934

SCHEMBL497934

FCC1CCCC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL604339 0.96
SCHEMBL169425 0.96
SCHEMBL21467045 0.96 CHRM5 (0.39)
SCHEMBL602116 0.92
SCHEMBL2686980 0.85 CHRM5 (0.33)
SCHEMBL322743 0.84
SCHEMBL13817489 0.83 SIGMAR1 (0.34)
SCHEMBL14616112 0.81 SIGMAR1 (0.33)
SCHEMBL18691426 0.81 EPHX1 (0.32)
SCHEMBL14472942 0.78 ALDH1A1 (0.44)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 221 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2019156541-A1 COMPOSITION FOR INCREASING EXPRESSION OF BLOOD COAGULATION FACTOR GENE, COMPRISING CORE-SHELL STRUCTURED MICROPARTICLES AS ACTIVE INGREDIENT 주식회사 지앤피바이오사이언스 2019-08-15 WO claimed
US-20180008523-A1 ONYCHOMYCOSIS TREATMENT SYSTEM AND METHOD DEVICEFARM INC (US) 2018-01-11 US claimed
US-20180000937-A1 ONYCHOMYCOSIS TREATMENT SYSTEM AND METHOD DEVICEFARM INC (US) 2018-01-04 US claimed
US-20170361078-A1 ONYCHOMYCOSIS TREATMENT SYSTEM AND METHOD NATIONAL SCIENCE FOUNDATION 2017-12-21 US claimed
US-20170354616-A1 ONYCHOMYCOSIS TREATMENT SYSTEM AND METHOD NATIONAL SCIENCE FOUNDATION 2017-12-14 US claimed
US-20170354815-A1 ONYCHOMYCOSIS TREATMENT SYSTEM AND METHOD NATIONAL SCIENCE FOUNDATION 2017-12-14 US claimed
EP-2044192-A2 ENHANCED OXYGEN CELL CULTURE PLATFORMS University of Miami (US) 2009-04-08 EP claimed
WO-2008006104-A2 ENHANCED OXYGEN CELL CULTURE PLATFORMS UNIVERSITY OF MIAMI (US) 2008-01-10 WO claimed
US-20080009027-A1 Enhanced Oxygen Cell Culture Platforms UNIVERSITY OF MIAMI (US) 2008-01-10 US claimed
US-7081092-B2 Methods and apparatus for monitoring and quantifying the movement of fluid IMCOR PHARMACEUTICAL COMPANY (US) 2006-07-25 US claimed
US-20050049484-A1 Methods and apparatus for monitoring and quantifying the movement of fluid TARGESON, INC. 2005-03-03 US claimed
US-6802813-B2 Methods and apparatus for monitoring and quantifying the movement of fluid IMCOR PHARMACEUTICAL CO. 2004-10-12 US claimed
US-20030220563-A1 Methods and apparatus for monitoring and quantifying the movement of fluid TARGESON, INC. 2003-11-27 US claimed
US-20020065467-A1 Methods and apparatus for monitoring and quantifying the movement of fluid SCHUTT ERNEST G (US) 2002-05-30 US claimed
WO-1998053855-A1 METHODS AND APPARATUS FOR MONITORING AND QUANTIFYING THE MOVEMENT OF FLUID ALLIANCE PHARMACEUTICAL CORP. (US) 1998-12-03 WO claimed
WO-1995004046-A1 COMPOUNDS AS PDE IV AND TNF INHIBITORS RHONE-POULENC RORER LIMITED (GB) 1995-02-09 WO claimed
US-20250009652-A1 COMPOSITIONS FOR RESPIRATORY DELIVERY OF ACTIVE AGENTS AND ASSOCIATED METHODS AND SYSTEMS PEARL THERAPEUTICS, INC. 2025-01-09 US disclosed
EP-4398368-A1 ELECTROLYTE SOLUTION, BATTERY CELL COMPRISING SAME, BATTERY AND ELECTRIC DEVICE Contemporary Amperex Technology Co., Limited (CN) 2024-07-10 EP disclosed
WO-1995004046-A1 COMPOUNDS AS PDE IV AND TNF INHIBITORS RHONE-POULENC RORER LIMITED (GB) 1995-02-09 WO disclosed
WO-1993017651-A2 ANTIVIRAL NUCLEOSIDE ANALOGUES, THEIR PRODUCTION AND USE Max-Delbrück-Centrum für Molekulare Medizin (DE) 1993-09-16 WO disclosed